European Medicines Agency recommends changes in use of ponatinib in order to minimise risk of thrombosis

The European Medicines Agency’s Committee for Medicinal Products for Human Use has made a number of recommendations to help minimise the risk of thrombs obstructing arteries or veins in patients taking the leukaemia medicine ponatinib (Iclusig). Recommendations follow a review of updated clinical trial data indicating that thrombosis was occurring at a higher rate than was observed at the time of the ponatinib’s initial authorisation. Read more here.